SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK

蚕蛹建议将他们的再生药物TP508重新用于治疗新冠肺炎，因为它能够减少急性肺损伤的影响，防止正常组织损伤和减少炎症。TP508在组织再生临床试验中具有现有的有效性，具有广泛的安全性(600名人体受试者没有不良反应)，并且生产的GMP具有足够的库存，可以进入新冠肺炎临床试验。该药物针对ARDS的潜在原因，包括内皮功能的丧失。

Chrysalis proposes to repurpose their regenerative drug, TP508, to treat COVID-19, due to its ability to reduce effects of acute lung injury, prevent normal tissue damage and reduce inflammation. TP508 has an existing efficacy profile in tissue regeneration clinical trials, an extensive safety profile (600 human subjects with no adverse effects), and is GMP manufactured with sufficient inventory to enter COVID-19 clinical trials. The drug addresses underlying causes of ARDS, including loss of endothelial function.